Emerging role of precision medicine in biliary tract cancers
Open Access
- 3 October 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in npj Precision Oncology
- Vol. 2 (1), 1-9
- https://doi.org/10.1038/s41698-018-0064-z
Abstract
Biliary tracts cancers (BTCs) are a diverse group of aggressive malignancies with an overall poor prognosis. Genomic characterization has uncovered many putative clinically actionable aberrations that can also facilitate the prognostication of patients. As such, comprehensive genomic profiling is playing a growing role in the clinical management of BTCs. Currently however, there is only one precision medicine approved by the US Food and Drug Administration (FDA) for the treatment of BTCs. Herein, we highlight the prevalence and prognostic, diagnostic, and predictive significance of recurrent mutations and other genomic aberrations with current clinical implications or emerging relevance to clinical practice. Some ongoing clinical trials, as well as future areas of exploration for precision oncology in BTCs are highlighted.This publication has 99 references indexed in Scilit:
- Role of microsatellite instability in the management of colorectal cancersDigestive and Liver Disease, 2013
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinomaBritish Journal of Cancer, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trialBritish Journal of Cancer, 2009
- FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1American Journal of Physiology-Renal Physiology, 2009
- Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expressionHepatology, 2008
- Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinomaBritish Journal of Cancer, 2007
- Sustained IL-6/STAT-3 Signaling in Cholangiocarcinoma Cells Due to SOCS-3 Epigenetic SilencingGastroenterology, 2007